Trial Profile
A phase IV trial to analyse the molecular prognostic factors for response to first-line treatment with bevacizumab and interferon in patients with advanced or metastatic renal cancer [Ensayo clinico fase IV.II para el analisis de los factores moleculares de pronostico de respuesta y beneficio clinico en pacientes con cancer renal metastasico o avanzado, tratados con bevacizumab e interferon como primera linea de tratamiento]
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 23 Aug 2011
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Interferon alpha-2a (Primary)
- Indications Renal cancer
- Focus Biomarker; Pharmacodynamics; Pharmacogenomic; Therapeutic Use
- Acronyms REVAMARK
- 23 Aug 2011 New trial record